CDI Labs

What CDI Labs does

CDI Labs is a privately-held biotechnology company and specialized contract research organization (CRO) that pioneered the field of "Seromics" — proteome-wide profiling of serum autoantibodies for biomarker discovery, target identification, and immunogenicity assessment. The company serves academic research institutions and pharmaceutical/biotech customers across North America, Europe, and Asia Pacific, with a named customer base of 200+ organizations including Mayo Clinic, Cleveland Clinic, Gustave Roussy, and KU Leuven.

CDI Labs operates three core proprietary technology platforms. The HuProt™ Human Proteome Microarray contains over 21,000 individually expressed, full-length, GST-purified recombinant human proteins covering 81% of the human proteome — described in source materials as the world's most comprehensive human proteome microarray. Complementing this are PhIP-Seq (Phage Display Immunoprecipitation Sequencing) services — VirScan® (68,000+ viral protein sequences), HuScan® (48,921 human proteins/isoforms), and MouseScan™ (50,135 mouse proteins) — which CDI commercialized as the first commercial provider of PhIP-Seq technology developed in Steve Elledge and Ben Larman's laboratories. A fourth platform, VirD™, displays functional membrane proteins (including >70% of non-odorant GPCRs) in authentic cell membranes for drug discovery. These platforms are backed by 350+ peer-reviewed publications validating the technology.

The business model is dual-pronged: project-based CRO service contracts for proteomics discovery work (autoantibody profiling, target ID, immunogenicity testing for cell/gene therapies, molecular glue screening via HuGlue®), and one-time product sales of HuProt microarray slides to labs with in-house scanning capability. Revenue mechanics are quote-based with Net 30 payment terms. Go-to-market combines direct enterprise sales (targeting pharma/biotech) with a network of regional distributors across UK, Europe, China, South Korea, Japan, and Singapore for mid-market and geographic reach, supported by scientific conference presence (SITC, HUPO, FOCiS), peer-reviewed publication strategy, and email/LinkedIn content marketing.

Name

CDI Labs

Legal name

CDI Laboratories, Inc.

Website

https://cdilabs.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

CDI Labs is a specialized proteomics CRO operating HuProt™ microarray and PhIP-Seq platforms for proteome-wide autoantibody profiling, serving 200+ academic and pharmaceutical customers across North America, Europe, and Asia Pacific.

Ownership category

akta.pro rank

Product category

Proteomics Services and Protein Microarrays

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

akta.pro secondary industries

Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC), Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)

Keywords

• Proteomics services
• Autoantibody profiling
• Protein microarray
• Biomarker discovery
• Target identification

Headquarters

HQ city

Mayaguez

HQ country

Puerto Rico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Proteomics Lab Services (CRO): CDI Labs operates as a specialized Contract Research Organization (CRO) providing proteomics services. Services include autoantibody biomarker discovery, viral exposure profiling, immunogenicity assessment, antibody specificity profiling, target identification, and custom protein/monoclonal antibody manufacturing. Revenue is generated through project-based service contracts with academic institutions and pharmaceutical companies.
2. HuProt Microarray Products: Sale of HuProt protein microarray slides and related products to labs with in-house microarray scanning capability. One-time product sale with potential for repeat orders.
3. PhIP-Seq Discovery Services: PhIP-Seq services including HuScan, VirScan, and MouseScan offered as custom discovery services using patient-derived antibodies in biological fluids (serum, plasma, CSF). Revenue generated through per-project assay fees.

Go-to-market motion3 records

Distribution channels11 records

Marketing channels7 records

Core offering

CDI Labs is a specialized Contract Research Organization (CRO) providing proteomics lab services for autoantibody biomarker discovery, viral exposure profiling, immunogenicity assessment, antibody specificity profiling, and target identification. The company offers both project-based service contracts and direct sale of proprietary HuProt human proteome microarray slides to research laboratories worldwide, with services powered by PhIP-Seq platforms (HuScan, VirScan, MouseScan) and VirD membrane protein microarray technology.

Product overview

CDI Labs is a specialized CRO and proteomics company pioneering the field of Seromics. The company offers a unified platform-plus-services architecture centered on three proprietary technology platforms: HuProt™ Human Proteome Microarray (the world's largest collection of full-length human proteins with 21,000+ proteins), PhIP-Seq services (HuScan®, VirScan®, MouseScan™ for epitope-level antibody profiling), and VirD™ Functional Membrane Protein Microarray (for GPCR and membrane protein analysis). These platforms are complemented by specialized services including Pan-isotype Profiling, Peptide Hormone PhIP-Seq, molecular glue discovery (HuGlue®), autoantibody profiling, target identification, and full-service CRO capabilities. The integrated portfolio enables customers to perform proteome-wide autoantibody biomarker discovery, viral exposure profiling, immunogenicity assessment, and target identification across autoimmune disease, oncology, neurology, infectious disease, and genetic disease research areas.

Differentiator

Problem solved

Functional benefit

Brands

• Monomabs: Individual monoclonal antibodies and protein products
• Antygen
• Grand Seromics
• Be Specific
• ImmuneProfiler
• FastMAb

Products and services

• HuProt™ Human Proteome Microarray The world's most comprehensive human proteome microarray, containing over 21,000 full-length, correctly-folded, GST-purified recombinant human proteins and isoform variants expressed in S. cerevisiae, covering more than 81% of the human proteome. Used for autoantibody profiling, biomarker discovery, and target identification by academic researchers and pharmaceutical companies.
• HuScan® PhIP-Seq Phage immunoprecipitation sequencing service detecting antibodies against 48,921 unique human proteins and protein isoforms using overlapping long peptides displayed on bacteriophage. Enables epitope-level autoantibody profiling against the entire human proteome for biomarker discovery, patient stratification, and target identification.
• VirScan® PhIP-Seq Phage immunoprecipitation sequencing service detecting antibodies against 68,000+ vertebrate viral protein sequences from human, mammalian, and other viral genomes. Maps an individual's lifetime of viral exposures through antibody profiling for infectious disease research and chronic disease etiology studies.
• VirScan® Exposome PhIP-Seq PhIP-Seq service detecting antibodies against 15,860+ non-human allergen protein sequences including biological, environmental, and industrial protein sequences for comprehensive exposome profiling.
• MouseScan™ PhIP-Seq Murine proteome PhIP-Seq service analyzing 50,135 mouse proteins and isoforms from the GRCm38.p5 genome. Enables autoantibody profiling in mouse models for preclinical research and therapeutic antibody development.
• VirD™ Functional Membrane Protein Microarray Microarray using virions to display functional membrane proteins including GPCRs, embedded in authentic cell membranes. Enables high-throughput drug discovery, biomarker discovery, and protein interaction studies for membrane proteins; displays over 70% of non-odorant G protein-coupled receptors.
• Peptide Hormone PhIP-Seq Library Specialized PhIP-Seq library enabling researchers to interrogate autoantibody responses against peptide hormones and hormone fragments. Addresses research in appetite regulation conditions, thyroid diseases, and other hormone-related autoimmune conditions. Offered exclusively through CDI Labs Canada.
• Pan-isotype Profiling Services Service enabling explicit detection of any antibody isotype or subclass (IgA1, IgA2, IgD, IgE, IgG1-4, IgM) binding using HuProt™ and VirScan® platforms. Provides comprehensive humoral immune response profiling beyond traditional pan-IgG analysis.
• HuGlue® Technology Access Program Molecular glue rational design technology enabling tripartite hit identification and biochemical validation at proteome-wide scale. Screens over 200,000 compounds per screen for molecular glue discovery and chemically induced proximity (CIP) studies.
• Specialized CRO Services Contract research services including antibody development, antibody pairs, protein production, cell therapy immunogenicity testing, CRISPR-Cas9 immunogenicity testing, and post-translational modification specificity profiling for academic and pharmaceutical clients.

Quantifiable outcome

• 21,000+ full-length proteins on HuProt microarray
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eleven partnerships are on record, tiered flagship and minor.

• Cancer Grand ChallengesflagshipStrategic or Co-development Partner · 4 March 2026CDI Labs joined the global Cancer Grand Challenges ATLAS team led by Institut Imagine's Paul Bastard. Co-investigator Dr Tyler Hulett will participate in research exploring the role of immune-modulating autoantibodies in cancer resistance. Team received up to $25 million over approximately five years to tackle the cancer avoidance challenge.
• Arrayjet Ltd.minorChannel Partner/ Reseller/ DistributorUK-based distribution partner for CDI Labs products and services.
• Cambridge Protein Arrays Ltd.minorChannel Partner/ Reseller/ DistributorCambridge, UK-based distribution partner covering European markets.
• PEPperPRINT GmbHminorChannel Partner/ Reseller/ DistributorHeidelberg, Germany-based distribution partner covering European markets.
• Filgen, Inc.minorChannel Partner/ Reseller/ DistributorNagoya, Japan-based distribution partner for Japanese markets.
• Beijing Protein Innovation Co., Ltd.minorChannel Partner/ Reseller/ DistributorBeijing, China-based distribution partner for Chinese markets.
• Wayen Biotechnologies Inc.minorChannel Partner/ Reseller/ DistributorShanghai, China-based distribution partner.
• Bosung Scientific Co., Ltd.minorChannel Partner/ Reseller/ DistributorSeoul, South Korea-based distribution partner.
• Gene On BiotechminorChannel Partner/ Reseller/ DistributorSeoul, South Korea-based distribution partner.
• Daemyung Science Co., Ltd.minorChannel Partner/ Reseller/ DistributorSeoul, South Korea-based distribution partner.
• ProBioscience Technologies Pte LtdminorChannel Partner/ Reseller/ DistributorSingapore-based distribution partner for Southeast Asian markets.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Olink Holding AB: Olink provides proximity extension assay (PEA)-based proteomics platforms for high-multiplex biomarker discovery, directly competing with CDI Labs' HuProt microarray and PhIP-Seq services in pharma biomarker and translational research markets.
• Standard BioTools (SomaLogic): Standard BioTools (formerly Fluidigm) acquired SomaLogic, operating the SomaScan platform measuring 11,000+ proteins via aptamer-based proteomics — directly competitive with CDI Labs' proteome-scale autoantibody and biomarker discovery offerings for pharma and academic researchers.
• Meso Scale Diagnostics (MSD): MSD provides multiplexed biomarker assay platforms using electrochemiluminescence, serving similar pharma biomarker discovery, immunogenicity testing, and translational research applications as CDI Labs' autoantibody and proteomics CRO services.
• GenScript: GenScript offers a broad portfolio of protein and antibody services including custom protein production, antibody development, and bioanalytical services — directly comparable to CDI Labs' specialized CRO offerings in protein/antibody products and biomarker discovery services.
• Abcam: Abcam is a leading antibody reagent and proteomics tools provider serving similar academic and pharma research customers; its expanded proteomics and immunoassay offerings overlap with CDI Labs' autoantibody profiling and target identification services.
• Cell Signaling Technology (CST): CST develops and manufactures high-quality antibodies and proteomics tools for academic and pharma research, with growing services in biomarker validation and target characterization — overlapping with CDI Labs' antibody validation and specificity profiling offerings.

Broad incumbents

• Bio-Techne: Bio-Techne is a diversified life sciences tools provider offering proteomics reagents (including the ProteinSimple brand), ELISA kits, and antibody products. While broader in scope, its proteomics offerings compete for similar pharma and academic proteomics budgets as CDI Labs.
• Luminex (DiaSorin): DiaSorin/Luminex offers xMAP multiplexed assay technology widely used in biomarker discovery and clinical research, competing with CDI Labs' multiplexed proteomics services for academic and pharma research customers.
• Charles River Laboratories: Charles River is a global CRO offering discovery and safety assessment services including biomarker and bioanalytical capabilities. While much broader than CDI Labs, it competes for large-pharma biomarker discovery and immunogenicity testing contracts.
• Eurofins Scientific: Eurofins is a global bioanalytical CRO with extensive protein and biomarker testing capabilities for pharma and academic customers. Its scale and global footprint make it a competitor for larger enterprise biomarker discovery contracts that CDI Labs targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cdi-labs
• Xx.com/cdi_labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CDI Labs